Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basal-bolus versus sliding scale insulin for prevention of postoperative surgical site infection in adults with type 2 diabetes
NL-OMON57124Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Incidence of surgical site infections within 30 days after surgery. Started Jan 2025; status: recruiting.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON57124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57124.